Lead author Kevin Hakimi discusses the background and results of the study, “Interim analysis of 

PADRES (prior axitinib as a determinant of outcome of renal surgery

 NCT03438708) clinical trial,” which he presented at the 

Conferences

Conference

In the PADRES trial, neoadjuvant axitinib facilitated partial nephrectomy in patients with clear cell renal cell carcinoma and complex masses with an imperative indication for nephron-sparing surgery but no viable pathway to receive the procedure.

Results of phase 3 PADRES trial of neoadjuvant axitinib in renal cell carcinoma